Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Acharya UH, Cassaday RD, Chapuis AG, Dhawale TM, Hendrie PC, Kiem HP, Lynch RC, Ramos J, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2019 Apr 25;133(17):1876-1887. doi: 10.1182/blood-2018-11-887067. Epub 2019 Feb 19.

PMID:
30782611
2.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Schoch G, Chapuis AG, Till BG, Kiem HP, Ramos JD, Shadman M, Cassaday RD, Acharya UH, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2019 Apr 11;133(15):1652-1663. doi: 10.1182/blood-2018-11-883710. Epub 2019 Feb 6.

PMID:
30728140
3.

Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.

Hay KA.

Br J Haematol. 2018 Nov;183(3):364-374. doi: 10.1111/bjh.15644. Epub 2018 Nov 8. Review.

PMID:
30407609
4.

CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era.

Hay KA, Turtle CJ.

Immunotherapy. 2018 Feb 1;10(4):251-254. doi: 10.2217/imt-2017-0162. No abstract available.

PMID:
29421980
5.

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, Riddell SR, Maloney DG, Boeckh M, Turtle CJ.

Blood. 2018 Jan 4;131(1):121-130. doi: 10.1182/blood-2017-07-793760. Epub 2017 Oct 16.

6.

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen J, Chung D, Harju-Baker S, Özpolat T, Fink KR, Riddell SR, Maloney DG, Turtle CJ.

Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 2017 Oct 12.

7.

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. Epub 2017 Sep 18.

8.

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG.

J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.

9.

Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.

Hay KA, Turtle CJ.

Drugs. 2017 Mar;77(3):237-245. doi: 10.1007/s40265-017-0690-8. Review.

10.

International travelers as sentinels for sustained influenza transmission during the 2009 influenza A(H1N1)pdm09 pandemic.

Davis XM, Hay KA, Plier DA, Chaves SS, Lim PL, Caumes E, Castelli F, Kozarsky PE, Cetron MS, Freedman DO; GeoSentinel Surveillance Network.

J Travel Med. 2013 May-Jun;20(3):177-84. doi: 10.1111/jtm.12025. Epub 2013 Mar 14.

11.

Inhibition of herpes simplex virus reactivation by dipyridamole.

Tenser RB, Gaydos A, Hay KA.

Antimicrob Agents Chemother. 2001 Dec;45(12):3657-9.

12.

Leukotropic herpesviruses in multiple sclerosis.

Hay KA, Tenser RB.

Mult Scler. 2000 Apr;6(2):66-8.

PMID:
10773849
13.

Herpes simplex virus latency after direct ganglion virus inoculation.

Hay KA, Edris WA, Gaydos A, Tenser RB.

J Neurovirol. 1998 Oct;4(5):531-8.

PMID:
9839650
14.

Inhibition of herpes simplex virus reactivation by dipyridamole in a mouse model.

Hay KA, Gaydos A, Tenser RB.

J Med Virol. 1996 Oct;50(2):198-203.

PMID:
8915888
15.
16.
17.

Secondary herpes simplex virus latent infection in transplanted ganglia.

Tenser RB, Edris WA, Gaydos A, Hay KA.

J Virol. 1994 Nov;68(11):7212-20.

18.

Neuronal control of herpes simplex virus latency.

Tenser RB, Edris WA, Hay KA.

Virology. 1993 Aug;195(2):337-47.

PMID:
8393231
19.
20.

Expression of herpes simplex virus type 2 latency-associated transcript in neurons and nonneurons.

Tenser RB, Edris WA, Hay KA, de Galan BE.

J Virol. 1991 May;65(5):2745-50.

22.
23.

Herpes simplex virus latent infection: reactivation and elimination of latency after neurectomy.

Tenser RB, Edris WA, Hay KA.

Virology. 1988 Nov;167(1):302-5.

PMID:
2847420
24.

Expression of type-common envelope antigens by herpes simplex virus type 2-transformed hamster cells.

Gupta P, Lausch RN, Hay KA, Rapp F.

Intervirology. 1980;14(1):50-6.

PMID:
6259083
25.
27.

Immunological studies with hamster cells transformed by cytomegalovirus and herpes simplex virus type 1.

Lausch RN, Murasko DM, Jones C, Hay KA.

IARC Sci Publ. 1975;(11 Pt 1):315-21.

PMID:
190134
28.

Spleen cell-mediated cytotoxicity of hamster cells transformed by Herpes simplex virus: evidence for virus-specific membrane antigen.

Lausch RN, Jones C, Christie D, Hay KA, Rapp F.

J Immunol. 1975 Jan;114(1 Pt 2):459-65.

PMID:
163859

Supplemental Content

Support Center